Competition and Price Cuts Slow Strong IO Momentum In China
Executive Summary
While strong growth in China's immuno-oncology sector continued in the last quarter, the momentum appears to be slowing, affecting by multiple factors including intense competition in the sector and price cuts related to reimbursement listing, while regulatory authorities have already warned about what they see as the wasting of resources on "redundant" development activities.
You may also be interested in...
Hengrui Takes Focused Approach Amid China Inc's Global Drive
China’s largest innovative domestic drug maker will only take global those products that play into its strengths, chairman Piaoyang Sun declares.
Venture Investors See China Remaining Attractive Despite High Valuations
In a vote of confidence, investors predict Shanghai IPOs to rise in 2022, while sluggish share performances in Hong Kong have made a public listing there more “a liquidity rather than an exit event.”
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.